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 Orally bioavailable small-molecule inhibitor of
 transcription factor Stat3 regresses human
 breast and lung cancer xenografts
 Xiaolei Zhang3,1, Peibin Yueb/I, Brent D. G. Pagec, Tianshu Lia, Wei Zhao3, Andrew T. Namanjad, David Paladino0,
 Jihe Zhao3, Yuan Chend, Patrick T. Gunningc, and James Turksona,b'2
 aBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL 32827; bCancer Biology and Experimental Therapeutics
 Programs, University of Hawaii Cancer Center, Honolulu, HI 96813; department of Chemistry, University of Toronto at Mississauga, Mississauga, ON, Canada,
 L5L 1C6; and department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, CA 91010
 Edited by James E. Darnell, The Rockefeller University, New York, NY, and approved April 13, 2012 (received for review January 4, 2012)
 Computer-aided lead optimization derives a unique, orally bioavail-
 able inhibitor of the signal transducer and activator of transcription
 (Stat)3 Src homology 2 domain. BP-1-102 binds Stat3 with an affin-
 ity (KD) of 504 nM, blocks Stat3-phospho-tyrosine (pTyr) peptide
 interactions and Stat3 activation at 4-6.8 цМ, and selectively inhib-
 its growth, survival, migration, and invasion of Stat3-dependent
 tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3
 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bd-xL,
 Survivin, VEGF, and Krüppel-like factor 8, which is identified as a
 Stat3 target gene that promotes Stat3-mediated breast tumor cell
 migration and invasion. Treatment of breast cancer cells with
 BP-1-102 further blocks Stat3-NF-icB cross-talk, the release of gran-
 ulocyte colony-stimulating factor, soluble intercellular adhesion
 molecule 1, macrophage migration-inhibitory factor/glycosylation-
 inhibiting factor, interleukin 1 receptor antagonist, and serine pro-
 tease inhibitor protein 1, and the phosphorylation of focal adhe-
 sion kinase and paxillin, while enhancing E-cadherin expression.
 Intravenous or oral gavage delivery of BP-1-102 furnishes micro-
 molar or microgram levels in tumor tissues and inhibits growth of
 human breast and lung tumor xenografts.
 Signal teins mediate transducer responses and activator to cytokines of transcription and growth (STAT) factors pro- (1). tei s ediate responses to cytokines a  growth factors (1).
 Recruitment via the Src homology 2 (SH2) domain to receptor
 phospho-tyrosine (pTyr) peptide motifs facilitates STAT phos-
 phorylation on a key tyrosyl residue by growth factor receptors
 and the Janus kinase (Jak) and Src kinase families. Phosphory-
 lation induces STAT-STAT dimerization through a reciprocal
 pTyr-SH2 domain interaction. The active dimers in the nucleus
 induce gene transcription by binding to specific DNA-respoñse
 elements in the promoters of target genes.
 The aberrant activation of Stat3 occurs in many human can-
 cers (2) and promotes tumor progression. The mechanisms of
 Stat3-mediated tumorigenesis include dysregulation of gene ex-
 pression that leads to uncontrolled growth and survival of tumor
 cells, enhanced tumor angiogenesis, and metastasis (3, 4). Tumor
 cell-associated constitutively active Stat3 also regulates proin-
 flammatory cytokine expression, including RANTES (regulated
 upon activation normal T cell expressed and secreted) and CXC
 motif chemokine 10 (CXCL10)/IFN-y-induced protein 10 (IP-
 10), and the induction of VEGF, interleukin 10 (IL-10), and
 other soluble factors, which in turn activate Stat3 in dendritic
 cells and inhibit their maturation. These events suppress tumor-
 immune surveillance (5). Reports also show Stat3-NF-KB cross-
 talk that supports the malignant phenotype (6, 7).
 Given its importance to cancer, Stat3 is the focus of drug
 discovery efforts, and the SH2 domain-pTyr interaction has
 gained much attention (2, 8-14). Although several dimerization-
 disrupting small-molecule Stat3 inhibitors have been reported
 (8, 9, 13-16), thus far none has reached the clinic for several
 reasons, including the suitability of the scaffolds and pharma-
 cokinetic issues. The leading dimerization-disrupting agent, S3I-
 201.1066 (17), was subjected to computer-aided lead optimiza-
 tion. We describe the derivation and characterization of the
 analog, BP-1-102, an orally bioavailable Stat3 SH2 domain li-
 gand that inhibits Stat3 activation and functions in vitro and in
 vivo, and thereby inhibits growth of mouse xenografts of human
 breast and non-small-cell lung cancers.
 Results
 Computer-Aided Design of BP-1-102 as an Analog of S3I-201.1066.
 Analysis of the structural composition and topology of the Stat3
 SH2 domain-binding "hotspot" shows three solvent-accessible
 subpockets on the protein surface, including the key pTyr705-
 binding region, which are accessed by S3I-201.1066 and most of
 the reported Stat3 inhibitors. BP-1-102 (Fig. L4) has appendages
 that promote interactions with all three subpockets (Fig. IS).
 Synthesis, chemical characterization, and detailed structural in-
 formation and further discussion are presented in SI Results, SI
 Materials and Methods, and Scheme SI.
 Inhibition of Stat3 Signaling and Function. BP-1-102 binds Stat3
 with a KD of 504 nM, determined by surface plasmon resonance
 (SPR) analysis (Fig. SL4). It preferentially disrupts Stat3 binding
 to phosphorylated, native high-affinity, IL-6R/gpl30 peptide
 (pTyr, pY904), with an IC50 of 4.1 jiM (Fig. S IB), as determined
 by fluorescence polarization (FP) assay, compared with its weaker
 activity against Stati binding to the IFN-y receptor peptide
 (GpYDKPHVL-NH2) or Stat5 binding to the erythropoietin re-
 ceptor peptide (GpYLVLDKW-NH2), with an IC50 of 25-30 jiM
 (Fig. SIC). Isothermal titration calorimetry (ITC) was further
 used to examine BP-1-102 effects on the interaction between
 pY904 and Stat3 (Fig. SID). ITC experiments in the absence and
 presence of BP-1-102 were conducted using identical sample
 concentrations and conditions (SI Materials and Methods). Pre-
 complexing Stat3 with BP-1-102 dramatically alters the pY904
 profile, with significantly reduced enthalpic contribution by ~6
 kcal/mol (Fig. S ID, Left vs. Right, respective y-axis intercepts).
 This result indicates a direct interference of pY904 binding to the
 SH2 domain. Similarly, the reverse ITC titration of BP-1-102 into
 free or pY904-bound Stat3 (Fig. SIE, Left and Right, respectively)
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 search; X.Z., P.Y., B.D.G.P., T.L., W.Z., A.T.N., and D.P. performed research; J.Z., Y.C., P.T.G.,
 and J.T. contributed new reagents/analytic tools; X.Z., P.Y., B.D.G.P., W.Z., A.T.N., J.Z.,
 Y.C., P.T.G., and J.T. analyzed data; and X.Z., P.Y., A.T.N., Y.C., P.T.G., and J.T. wrote
 the paper.
 The authors declare no conflict of interest.
 This article is a PNAS Direct Submission.
 Freely available online through the PNAS open access option.
 1X.Z. and P.Y. contributed equally to this work.
 2To whom correspondence should be addressed. E-mail: jturkson@cc.hawaii.edu.
 This article contains supporting information online at www.pnas.org/lookup/suppl/doi: 10.
 1 073/pnas. 1 1 2 1 6061 09/-/DCSupplemental.
 >-
 a
 О
 о
 и
 <
 S
 oc
 <
 z
 CL
 >
 ее
 h-
 l/t
 I
 Ш
 X
 и
 www.pnas.org/cgi/doi/10.1073/pnas.1121606109 PNAS | June 12, 2012 | vol.109 | no. 24 | 9623-9628
This content downloaded from 132.170.192.79 on Thu, 13 Dec 2018 14:23:24 UTC
All use subject to https://about.jstor.org/terms
 Fig. 1. (A) Structure of BP-1-102. ( В ) Computational modeling of BP-1-102
 binding to the Stat3 SH2 domain. (Left) Monomer Stat3 with the solvent-
 accessible surface of the SH2 domain (off-white) color-coded with hydro-
 philic (blue) and hydrophobic residues (pink) and overlaid with BP-1-102
 (cyan). {Right) The three solvent-accessible subpockets of the 5H2 domain
 surface accessed by BP-1-102, with the pentafluorobenzene sulfonamide
 component projecting into the third subpocket composed of Lys591, Glu594,
 Ile634, and Arg595.
 confirms that these two ligands interfere with each other's binding
 at the SH2 domain. In fact, titration of BP-1-102 to pY904-bound
 Stat3 shows an increasing endothermic profile (heat absorption),
 consistent with BP-1-102 displacing pY904 from Stat3. Taken
 together, these results suggest direct competition of the ligands
 to the same binding site on the SH2 domain.
 The R2 relaxation filter NMR approach (18) was used to study
 pY904 binding to Stat3 and verify that BP-1-102 competes with
 pY904. The pY904 signal (Fig. SI F, black tracing) was attenuated
 upon addition of Stat3 (Fig. SI F, red tracing), indicating binding.
 Addition of BP-1-102 resulted in further attenuation (Fig. S1F,
 blue tracing), suggesting direct interference with pY904 binding
 to the SH2 domain. The interference could be more significant if
 BP-1-102 did not form soluble aggregates in the aqueous envi-
 ronment used for NMR studies (Fig. SI G and SI Materials and
 Methods). This result further supports the findings by SPR, FP,
 and ITC. BP-1-102 inhibits Stat3 DNA-binding activity in vitro,
 with an IC50 value of 6.8 ± 0.8 [iM (Fig. 24), and preferentially
 inhibits Stat3-Stat3, over Statl-Stat3, Statl-Statl, or Stat5-Stat5
 DNA-binding activity (Fig. 2B), as measured by EMSA analysis
 (9, 11, 17). BP-1-102 is substantially improved over the lead, S3I-
 201.1066 (SPR, KD of 2.7 [iM; FP, IG>0 of 23 цМ; EMSA, IQ0 of
 36 jiM) (17).
 BP-1-102 inhibited constitutive Stat3 DNA-binding activity
 (Fig. 2 С and Fig. S24), Tyr705 phosphorylation (Fig. 2 D and E ,
 and Fig. S2 B, pYStat3), and Stat3-dependent luciferase reporter
 (pLucTKS3) (19, 20) induction (Fig. S2C, TKS3). The inhibition
 occurs in a dose- and time-dependent manner and as early as 30
 min (Fig. 2 С and D and Fig. S2 B). Stat3 is distributed in the
 cytoplasm, nucleus, and mitochondria (Fig. 2D and Fig. S2 D and
 E). Levels of pY705Stat3 are higher in the nucleus than in the
 cytoplasm, except in DUI 45 cells (Fig. S2 D and E ), and are
 undetectable in mitochondria (Fig. S2£). BP-1-102 treatment at-
 tenuated both nuclear and cytoplasmic pY705Stat3 (Fig. 2 D and
 Fig. S2E). By contrast, BP-1-102 had little or no effect on phos-
 pho-Shc, Src, Jak-1/2, Erkl/2, or Akt levels (Fig. 2 E), induction
 of the Stat3-independent luciferase reporter, pLucSRE, which is
 driven by the serum-response element (SRE)/c-fos promoter (19,
 20) (Fig. S2C, SRE), or the phosphorylation of many cellular
 kinases (Table SI). BP-1-102 treatment further suppressed c-Myc,
 Cyclin Dl, Bcl-xL, Survivin, and VEGF expression (Fig. 2 F),
 which occurred subsequent to Stat3 inhibition (Fig. 2D). Thus,
 inhibition of aberrantly active Stat3 suppresses Stat3-dependent
 gene regulation.
 BP-1-102 Selectively Suppresses Growth, Survival, Malignant Transfor-
 mation, Migration, and Invasion of Malignant Cells Harboring Consti-
 tutively Active Stat3. Consistent with the dependency on abnormal
 Stat3 signaling of NIH 3T3/v-Src fibroblasts and malignant cells
 Fig. 2. BP-1-102 inhibits Stat3 activation. ( A and B) EMSA analysis of nuclear
 extracts of equal total protein containing activated STATs, preincubated with
 0-20 (iM BP-1-102 for 30 min before incubation with a radiolabeled (A and B,
 /') hSIE probe that binds Stati and Stat3 or ( В , /'/') mammary gland factor el-
 ement probe that binds Stat5. (C) EMSA analysis using an hSIE probe for
 Stat3 DNA-binding activity in nuclear extracts of equal total protein pre-
 pared from the designated tumor cells treated with 0-20 |iM BP-1-102. ( D-F )
 Immunoblots of pY705Stat3, Stat3, histone deacetylase 1 (HDAC1), pY239/
 240Shc, She, pY1 022/1 023Jak1, Jak, pY1 007/1 008Jak2, Jak2, p416Src, Src,
 pT202/Y204Erk1/2, Erk1/2, pY473Akt, Akt, c-Myc, Cyclin D1, Bcl-xL, Survivin,
 VEGF, or ß-actin in cytosolic (Cyto) or nuclear (Nuc) fractions or whole-cell
 lysates of equal total protein prepared from (D) MDA-MB-231 cells treated
 with 1 0 ^iM BP-1 -1 02 for 0-6 h, or (E and F) the indicated cells treated with 0-
 20 цМ BP-1-102 for 24 h. The positions of STAT-DNA complexes or proteins in
 the gels are labeled; control lanes (0) represent treatment with 0.05% DMSO.
 Data are representative of three or four independent determinations.
 harboring aberrantly active Stat3 for the transformed phenotype
 (2, 4, 19, 20), BP-1-102 treatment suppressed cell proliferation,
 anchorage-dependent and -independent growth, and colony num-
 bers of NIH 3T3/v-Src (v-Src), MDA-MB-231 (231), Panc-1,
 DU145, and A549 cells harboring aberrantly active Stat3 (Fig. ЗА
 and Fig. S3 A and B). Overexpression of the artificially engi-
 neered, constitutively active Stat3C mutant (21) rendered MDA-
 MB-231 cells refractory to BP-1-102 (Fig. ЗА, 231/St3C). Stat3C
 expressed in cells is insensitive to BP-1-102 (Fig. S2F). More-
 over, BP-1-102 induced apoptosis in MDA-MB-231 cells (Fig.
 3 B, Eower , bars 3 and 4), which was attenuated (Fig. 35, Lower ,
 bars 6 and 7 vs. bars 3 and 4) by overexpressing Flag-tagged Stat3
 SH2 domain (Fig. 3B, Upper , immunoblot), the target for BP-1-
 102. The data together show the specificity of BP-1-102 effects
 against Stat3-dependent tumor cells, which are dependent on
 disrupting Stat3 SH2 domain function. Treatment with BP-1-102
 for 16 h, before observing the effect on proliferation (Fig. S3/4,
 Insets), inhibited migration (Fig. 3C and Fig. S3C) and in-
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 Fig. 3. BP-1-102 induces antitumor cell effects in vitro and suppresses tu-
 mor-supporting factors. (A) Cultured MDA-MB-231, DU145, Panc-1, and NIH
 3T3/v-Src cells harboring aberrantly active Stat3 and NIH 3T3, NIH 3T3/v-
 Ras, mouse thymus stromal epithelial cells, TE-71, Stat3-null mouse embry-
 onic fibroblasts (Stat3~/_ MEFs), cisplatin-sensitive ovarian cancer cells,
 A2780S cells that do not, were treated once with 0-30 цМ BP-1-102 and sub-
 jected to CyQUANT cell proliferation assay. ( В ) Annexin V/flow cytometry
 analysis of MDA-MB-231 cells transfected with pcDNA-3 (mock) or Flag-
 tagged Stat3 (St3) SH2 domain and treated with 0-15 цМ BP-1-102 (Lower);
 Flag immunoblot (Upper). (C) Cultured malignant cells were treated with BP-
 1-102, wounded, and allowed to migrate into a denuded area. (D) Number
 of invaded MDA-MB-231 cells in a BioCoat invasion chamber assay and the
 effects of BP-1-102. (E and F) Imm'unoblotting analysis of whole-cell lysates
 prepared from MDA-MB-231 cells (E and F, i) treated with 0-15 цМ BP-1-102
 or (F, ii) transfected with control (-) or Stat3 siRNA (+) and probing for FAK,
 pY576/577FAK, paxillin, pY1 18paxillin, E-cadherin, Snail, KLF8, EPSTI1, or
 ß-actin. (G) Number of invaded MDA-MB-231 cells in a BioCoat invasion
 chamber assay and the impact of KLF8 overexpression on BP-1-102 effects.
 (H-J) Immunoblotting analysis of (H) whole-cell (WC), nuclear (Nuc), or cy-
 tosolic (Cyto) lysates, (I) immunecomplexes of Stat3 (Upper) or RelA (Lower)
 prepared from MDA-MB-231 cells treated with 0-15 цМ BP-1-102, or (J)
 whole-cell lysates of MDA-MB-231 cells transfected with control (-) or Stat3
 siRNA (+) and probing for pY705Stat3, Stat3, pS536RelA, RelA, ß-actin, or
 HDAC1. (K) G-CSF, sICAM, and MIF/GIF levels assayed in conditioned medium
 from cultures of MDA-MB-231 cells treated for 48 h with BP-1-102. Positions
 of proteins in the gel are shown. Data are representative of three or four
 independent determinations. Values, mean ± SD, n = 4 or 9. *P < 0.05, **P <
 0.01, ***P< 0.005.
 vasiveness (Fig. 3D and Fig. S3D) of Stat3-dependent tumor
 cells. By contrast, BP-1-102 had little or no similar antitumor cell
 effects on a range of nontarget cells, including normal NIH 3T3
 (3T3), mouse thymus stromal epithelial cells, TE-71, Stat3-null
 mouse embryonic fibroblasts (-/-MEFs), NIH 3T3/v-Ras (v-Ras),
 or A2780S cells that do not harbor aberrantly active Stat3 (Fig. 3
 A and С and Fig. S3 A-C). These effects are consistent with the
 down-regulation of known Stat3-inducible genes (Fig. 2 F) (1, 3, 4).
 BP-1-102 Modulates Factors That Regulate Cell Adhesion, Cell-Cell
 Interactions, Motility, Migration, and Invasion. Except for Stat3 as-
 sociation with phospho-paxillin, focal adhesion kinase (FAK),
 and Src (22), little is known about the Stat3-dependent molec-
 ular events that promote tumor progression. BP-l-102-treated
 breast cancer MDA-MB-231 cells showed decreased phosphor-
 ylation of paxillin and FAK and increased E-cadherin expression
 (Fig. 3 E). To exclude nonspecific effects, ovarian cancer A2780S
 cells that do not harbor aberrantly active Stat3 were treated with
 BP-1-102. No changes in p-FAK or p-paxillin levels were ob-
 served (Fig. 3 E). The data that Stat3 inhibition occurs as early as
 30 min (Fig. 2D), when FAK and paxillin are little affected (Fig.
 S4), suggest that the decreased p-FAK and p-paxillin levels at
 24 h (Fig. 3 E) are secondary events to Stat3 inhibition. BP-1-102
 further suppressed Snail expression (Fig. 3 E), a Stat3-regulated
 gene that controls E-cadherin expression.
 FAK promotes Krüppel-like factor (KLF)8 induction (23).
 KLF8 and the tumor-stroma interaction factor, epithelial-stro-
 mal interaction 1 (EPSTI1) protein, promote tumor cell spread
 and invasiveness (24, 25). BP-l-102-treated breast cancer cells
 showed reduced KLF8 and EPSTI1 levels (Fig. 3 F, /), which was
 validated by Stat3 knockdown by siRNA (Fig. 3 F, ii). Further-
 more, in normal NIH 3T3 fibroblasts, transiently cotransfected
 with the KLF8 promoter-driven luciferase reporter (pLucKLF8)
 and v-Src vector, the activation of Stat3 by v-Src (20) induced
 plucKLF8 expression by over twofold, which was repressed by
 BP-1-102 (Fig. S5/4). The KLF8 promoter has three putative
 Stat3 binding sites (Fig. S5 B, i). Site-specific mutation in the
 nucleotide sequence -253/-245 (site 1) severely impaired the
 mutant pLucKLF8/-253T/G reporter induction (Fig. S5A, com-
 pare bars 2 and 5). In vitro DNA-binding/EMSA analysis further
 showed a strong Stat3 binding to an oligonucleotide probe in-
 corporating site 1 (-253/-245), compared with the standard high-
 affinity ш-inducible element (hSIE) probe, which was diminished
 by blocking anti-Stat3 antibody in a supershift assay (Fig. S5 B,
 ii). No Stat3 binding was observed to site 2 or 3 (Fig. S5 B, ii),
 although we do not exclude the possibility they contribute to Stat3
 responsiveness. Thus, Stat3 directly induces the KLF8 gene.
 To further study KLF8 importance, we evaluated BP-1-102
 effects on cell motility and invasiveness in a KLF8 overexpression
 or knockdown background. By contrast to inhibition of invasive-
 ness of the wild-type cells (Fig. 3 D and G, bar 2), KLF8 over-
 expression (24) in MDA-MB-231 cells abolished BP-1-102 effects
 (Fig. 3 G, bars 3-5). Further, studies using tetracycline-inducible
 KLF8 shRNA (24) in MDA-MB-23 1-K8ikd cells show that KLF8
 knockdown, as expected, suppressed cell migration (Fig. S5C,
 compare bar 2 vs. 5) and invasiveness (Fig. S5D, compare bar
 2 vs. 5) and in turn minimized the BP-l-102-induced effect
 that is otherwise observed in the wild-type, uninduced cells (Fig.
 S5 С and D, compare the relative change between bars 2 and 3 to
 that of bars 5 and 6). Thus, KLF8 expression is one of the un-
 derlying mechanisms of Stat3-mediated tumor cell migration and
 invasiveness.
 BP-1-102 Represses Stat3-NF-icB Cross-Talk and the Extracellular
 Production of Soluble Factors. Stat3 cross-talks with factors such
 as NF-kB in the tumor microenvironment (6, 7) that redirect
 inflammation signal for oncogenic functions. BP-l-102-mediated
 attenuation of nuclear and cytoplasmic pY705Stat3 and of nu-
 clear total Stat3 led to decreased nuclear pRelA and total RelA
 levels (Fig. ЗЯ), whereas cytoplasmic RelA and pRelA levels
 appeared unchanged. To investigate the concurrent decline in
 c ear RelA, we focused on the pStat3-pRelA complex (26),
 which is detected in the nucleus by coimmunoprecipitation anal-
 ysis (Fig. 3/, lane 1) and as colocalization in immunofluorescence/
 confocal microscopy (Fig. S&4, control, merged). BP-1-102 treat-
 ment diminished the pStat3-pRelA interaction (Fig. 3/, lane 2
 and Fig. S6/4, compare 25 jiM, 16 h to control), which was val-
 idated by Stat3 knockdown by siRNA (Fig. 3 J). By contrast, BP-
 1-102 treatment had no effect on IicB-RelA interactions (Fig.
 S6 B). Per the published report (26) that nuclear Stat3-NF-KB
 complex promotes nuclear NF-кВ retention, BP-l-102-mediated
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 inhibition of activated Stat3 diminishes nuclear Stat3 that in turn
 down-regulates nuclear pNF-кВ.
 To explore further the BP- 1-102 effect on Stat3 cross- talks, we
 examined the production of soluble factors by tumor cells. Cul-
 ture medium from BP-l-102-treated MDA-MB-231 cells showed
 lower granulocyte colony-stimulating factor (G-CSF), soluble in-
 tercellular adhesion molecule (sICAM) 1, and macrophage migra-
 tion-inhibitory factor (MIF)/glycosylation-inhibiting factor (GIF)
 levels (Fig. ЪК). Moreover, treatment of cells with exogenous G-
 CSF further induced Stat3 and RelA phosphorylation above
 constitutive levels (Fig. S6C, compare lanes 1 and 3) and conse-
 quently blocked the BP-l-102-repressive effect (Fig. S6C, com-
 pare lanes 2 and 4). Thus, BP-1-102 inhibits the production of
 soluble factors by tumor cells.
 BP-1-102 Inhibits Growth of Human Breast and Non-Small-Cell Lung
 Tumor Xenografts and Modulates Stat3 Activity, Stat3 Target Genes,
 and Soluble Factors in Vivo. BP-1-102 inhibited growth of mouse
 xenografts of human breast (MDA-MB-231) and non-small-cell
 lung (A549) tumors that harbor aberrantly active Stat3 when
 administered via i.v. (tail vein injection, 1 or 3 mg/kg, every 2 or
 3 d for 15 d) (Fig. 4 A and C) or oral gavage (3 mg/kg, 100 |iL,
 every day) (Fig. AB). No significant changes in body weights (Fig.
 S7 A and B) or obvious signs of toxicity, such as loss of appetite,
 decreased activity, or lethargy, were observed during the efficacy
 study or in a separate toxicity study where animals were dosed
 1 or 3 mg/kg i.v. every 2 or 3 d for 21 d and monitored over 42 d,
 as shown by body weight and gross anatomical examination of
 organs (Fig. S7 С and D). The apparent stronger antitumor re-
 sponse to oral gavage is likely due to the daily dosing.
 Analysis of tumor tissue lysates shows decreased Stat3 DNA-
 binding activity in treated tumors (T1 and T3) compared with
 nontreated control (Fig. SSA, Upper). Immunoblotting analysis
 of lysates from residual tumor tissues also showed suppression of
 pY705Stat3, c-Myc, Cyclin Dl, Bcl-xL, Survivin, and VEGF ex-
 pression that occurred in a dose-dependent manner (Fig. SSA,
 Lower), decreased pFAK, phospho-paxillin, KLF8, and EPSTI1
 levels, enhanced E-cadherin expression (Fig. S SB), and dimin-
 ished pRelA (Fig. S8C), compared with control tumors. Analysis
 of residual tumor tissue lysates (T1 and T3) also showed
 suppression of sICAM- 1, MIF/GIF, serpin peptidase inhibitor,
 clade E (nexin, plasminogen activator inhibitor type 1), member 1
 Fig. 4. Human breast and non-small-cell lung tumor xenografts and the
 antitumor effects and in vivo pharmacokinetic properties of BP-1-102. ( A-C )
 Mice bearing MDA-MB-231 ( A and B) or A549 (C) tumors were administered
 BP-1-102 via i.v., 1 or 3 mg/kg or vehicle (0.05% DMSO in PBS) every 2 or 3 d
 or oral gavage, 3 mg/kg or vehicle (0.05% DMSO) every day. Tumor sizes,
 measured every 2 or 3 d, were converted to tumor volumes and plotted
 against days of treatment. (D and E) Graphical representations of BP-1-102
 levels in (D) plasma samples collected from mice 15-360 min post-single
 dosing of 3 mg/kg via i.v. (/) or oral gavage (/'/'), or (£) tumor tissues extracted
 15 min or 24 h after the last dosing with 3 mg/kg, i.v. or oral gavage. Values,
 mean ±<SD, n = 7-10. **P < 0.01, and ***P < 0.005.
 (Serpine 1), and interleukin 1 receptor antagonist (IL-1RA) pro-
 duction (Fig. S8D), whereas G-CSF was undetectable.
 BP-1-102 Is Detectable at Micromolar Concentrations in Plasma and in
 Micrograms in Tumor Tissues. In vivo pharmacokinetic profiling of
 plasma samples from a cohort of three mice collected at 15, 30,
 60, 90, 180, and 360 min post-i.v. treatment (3 mg/kg) with a
 single dose showed BP-1-102 levels upward of 35 'iM at 15 min
 postdosing, which declined by 30 min to a steady 5-10 цМ level
 for up to 6 h (Fig. AD, i), whereas plasma samples post-oral
 dosing at 3 mg/kg showed peak BP-1-102 levels of about 30 цМ
 at 30 min, which steadily declined to 5-10 |iM over a 6-h period
 (Fig. AD, ii). Thus, blood levels over a prolonged period can
 exceed the IC5o values against Stat3. Moreover, BP-1-102 was
 detectable at 55 or 32 [ig/g tumor tissue, respectively, for i.v. or
 oral delivery of 3 mg/kg, 15 min after the last dosing, and at 25
 or 15 j-ig/g tumor tissue, respectively, for i.v. or oral delivery of
 3 mg/kg, 24 h after the last dosing (Fig. AE). Data together
 confirm that BP-1-102 is orally bioavailable and that the agent
 accumulates in tumor tissues at levels sufficient to inhibit aber-
 rantly active Stat3 functions and inhibit tumor growth.
 Discussion
 BP-1-102 is designed as a Stat3-Stat3 dimerization disruptor
 with optimized structural features to enhance inhibitory activity.
 Stat3 binding is supported by SPR, FP, ITC, and NMR data that
 also show disruption of Stat3 SH2 domain-pTyr peptide inter-
 action. Modeling predicts it binds to the three solvent-accessible
 subpockets of the Stat3-Stat3 dimer interface (27) (Fig. IB), mak-
 ing hydrogen bonds in the third subpocket, and additional inter-
 actions with the charged Lys side chain via the unique pentafluo-
 robenzene, which contribute to increased activity. Binding at the
 pTyr peptide binding site of the SH2 domain would disrupt pre-
 existing Stat3-Stat3 dimers and block de novo Stat3 phosphoryla-
 tion at the receptor and dimer formation. The reduced nuclear
 pYStat3 is the combination of diminished nuclear translocation,
 due to activation inhibition, and Stat3 nuclear exit upon dimer
 disruption (28).
 The antitumor cell effects and the in vivo efficacy of BP-1-102
 are consistent with thwarting Stat3's key role in tumorigenesis,
 including dysregulation of gene expression leading to uncontrolled
 growth, survival, and angiogenesis (2, 4). The present study iden-
 tifies KLKF8 (24) as a Stat3 target gene that promotes motility,
 migration, and invasion. Further, the induction of FAK and paxillin
 phosphorylation, EPSTI1 (25) expression, and the down-regulation
 of E-cadherin likely contribute to Stat3-mediated malignant pro-
 gression (Fig. S9). Both KLF8 and EPSTI1 promote epithelial-
 mesenchymal transition and tumor invasiveness and are up-regu-
 lated in invasive and metastatic tumors (24, 25), as is aberrantly
 active Stat3. The induction of these events would repress epithelial
 cell assembly and cadherin-based cell-cell adhesions and promote
 dynamic regulation of cell-matrix adhesions that would drive tu-
 mor migration and invasiveness.
 In the strong interplay of tumor cells with the microenviron-
 ment, Stat3 modulates inflammatory cytokines/chemokines that
 in turn suppress immune and inflammatory cells' functions and
 tumor-immune surveillance (6). Of the factors regulated by Stat3
 (5), IL-6, VEGF, and NF-кВ also in turn promote Stat3 activa-
 tion or are in cross-talks that perpetuate protumorigenic pro-
 cesses (6, 7, 26). The present study raises the possibility that
 sICAM (29), G-CSF, MIF/GIF, Serpine 1, and IL-1RA induction
 support Stat3-dependent tumor processes, including angiogen-
 esis (30) (Fig. S9); MIF is overexpressed in breast cancer (31)
 and promotes disease progression (32), Serpine 1 expression
 correlated with advanced clear cell renal cell carcinoma and
 promoted tumor angiogenesis and aggressiveness (33). Further,
 IL- IRA blocked IL-l-induced antitumor cell effects in prostate
 cancer cells (34) and enhanced the proliferation (35) and growth
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 of hepatic and glioblastoma cells (36), and sIL-IRA mRNA
 expression correlated with lymph node and hepatic metastases in
 gastric carcinoma patients (37). BP-l-102-mediated repression
 of these tumor-supporting factors likely contributes to its anti-
 tumor effects.
 We present a unique Stat3 inhibitor, BP-1-102, that sufficiently
 accumulates in tumor tissues and induces antitumor responses in
 human tumor xenografts that harbor aberrantly active Stat3. The
 oral bioavailability of BP-1-102 represents a substantial advance-
 ment in the discovery of small-molecule Stat3 inhibitors as unique
 anticancer agents.
 Materials and Methods
 Cells and Reagents. NIH 3T3, NIH 3T3/v-Src, and NIH 3T3/v-Ras cells, the human
 breast cancer line MDA-MB-231 and counterpart expressing inducible KLF8
 shRNA (231-K8ikd), and human prostate (DU145), non-small-cell lung (A549),
 and pancreatic (Panc-1) cancer cells have all been previously reported (11,
 17, 20, 24). Stat3-dependent (pLucTKS3), Stat3-independent (pLucSRE), and
 pLucKLF8 luciferase reporters, and the v-Src, ß-galactosidase, Stat3 SH2 do-
 main, Stat3C, and pLVUT-tTR-KRAB-KLF8 vectors have all been reported
 (9, 19-21, 23, 24). Other reagents are the Human Cytokine Array Kit (R&D
 Systems), G-CSF (Sigma-Aldrich) used at 100 ng/mL, and Stati and Stat5
 proteins (SignalChem). Primary antibodies used were anti-Stat3, pStat3, pSrc,
 Src, pErk1/2, Erk1/2, pJakl, Jak1, Jak2, pJak2, pShc, She, Cyclin D1, c-Myc, Bcl-
 xL, Survivin, Akt, pAkt, pRelA, RelA, pFAK, FAK, phospho-paxillin, paxillin,
 E-cadherin, HDAC1, Snail, and ß-actin (Cell Signaling Technology), VEGF
 (Santa Cruz Biotechnology), Flag and EPSTI1 (Sigma-Aldrich), and KLF8 (24).
 Cells were grown in DMEM containing 10% (vol/vol) heat-inactivated FBS.
 Cloning and Protein Expression. Molecular cloning, expression, and purifica-
 tion of His-tagged Stat3 have previously been reported (17). The cloning of
 the pXJ-FLAG-Stat3 SH2 domain and mutant KLF8 promoter is described in
 detail in SI Materials and Methods.
 Nuclear Extract Preparation, Gel Shift Assay, and Densitometrie Analysis. Stud-
 ies and analysis were carried out as previously described (9, 20, 28). Details are
 provided in SI Materials and Methods.
 Immunoprecipitation and Western Blotting Analyses. Studies were performed
 as previously described (9, 17, 28). Details are provided in SI Materials
 and Methods.
 Cell Viability, Proliferation, Colony Survival, and Wound-Healing Assays. Studies
 were performed as previously reported (17). Details are provided in SI
 Materials and Methods.
 Transient Transfection of Cells, Luciferase, and Apoptosis Assays. Studies were
 performed as previously reported (9, 20). After seeding for 12-24 h, cells
 were transfected with designated plasmid or siRNA, treated or not with BP-
 1-102, and processed for luciferase, immunoblotting, or Annexin V/flow
 cytometry analysis. Details of the Stat3 siRNA and studies are provided in SI
 Materials and Methods.
 Immunostaining with Laser-Scanning Confocal Imaging. Studies are described
 in detail in SI Materials and Methods.
 Fluorescence Polarization Assay. Assays were conducted as previously repor-
 ted (17).
 Surface Plasmon Resonance Analysis. Studies were performed as previously
 reported (17).
 Cell Migration/Invasion Assays. Experiments were carried out and quantified
 as previously reported (9, 24, 28). Details are provided in SI Materials
 and Methods.
 Cytokine Analysis. The assay is described in detail in SI Materials and Methods.
 Tumor Xenografts, Efficacy, and Pharmacokinetic Studies. Studies were per-
 formed as previously reported (9, 17, 28). BP-1-102 concentrations in mouse
 plasma and tumor tissue lysates were assayed using a validated analytical
 procedure via HPLCy. Details are provided in SI Materials and Methods.
 Statistical Analysis. Statistical analysis was performed on mean values using
 Prism (GraphPad Software). The significance of differences between groups
 was determined by the paired ttest at *P< 0.05, **P< 0.01, and ***p< 0.005.
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